by The PD-1 and PD-L1 inhibitor drugs work by blocking proteins called PD-1 and PD-L1, which help tumors hide from the immune system. When blocked, these checkpoints help enable the immune system to recognize and fight cancer cells. These checkpoint inhibitor drugs have become a key part of treatment for many types of cancer including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, Hodgkin’s lymphoma and Merkel cell carcinoma. The PD-1 and PD-L1 inhibitor market consists of drugs from major pharmaceutical companies including Merck, Bristol-Myers Squibb, Roche and AstraZeneca. The advantages of these drugs over traditional chemotherapy include more targeted mechanism of action, improved survival rates and fewer side effects for patients.
The global PD-1 and PD-L1 inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 19% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the PD-1 and PD-L1 inhibitor market is the development of combination therapies. Various clinical trials are exploring combining PD-1/PD-L1 inhibitors with other immunotherapies like CTLA-4 inhibitors or with targeted therapies. This is aimed at further enhancing anti-tumor immune response. Another notable trend is the increasing approvals for new cancer indications beyond melanoma, lung cancer and renal cell carcinoma. Ongoing research is evaluating efficacy of these drugs in cancers of the head and neck, bladder, Hodgkin’s lymphoma, liver and others. Such label expansions are expected to fuel market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: In the PD-1 and PD-L1 inhibitor market, high capital requirements and regulatory barriers exist, posing a low threat of new entrants.
Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of substitute treatment options for cancer.
Bargaining power of suppliers: A few big pharmaceutical companies dominate the supply side, giving them strong bargaining power over other players in the market.
Threat of new substitutes: Emerging novel immunotherapies indicate a medium threat from substitutes in the long run.
Competitive rivalry: well-established players compete intensely on drug pricing, which is high.
Key Takeaways
The global PD-1 And PD-L1 Inhibitor Market Demand is expected to witness high growth over the forecast period. Regional analysis comprises North America dominates the market currently due to favorable coverage and reimbursement policies. Europe and Asia Pacific regions are the fastest growing markets due to increasing patient preference for immunotherapies over conventional cancer treatments in these regions.
Key players operating in the PD-1 and PD-L1 inhibitor market are Bristol-Myers Squibb, Merck & Co., Roche, AstraZeneca, Novartis and Pfizer. Bristol-Myers Squibb and Merck & Co. together hold majority market share currently. AstraZeneca’s Imfinzi and Pfizer’s Bavencio are emerging as topselling PD-L1 inhibitors.
The global PD-1 and PD-L1 inhibitor market size for 2023 is estimated to be US$ 39.83 Bn. Rising cancer incidence and increasing awareness about immune checkpoint inhibitors are major factors fueling market growth over the forecast period of 2023 to 2030.
Note:
Source: Coherent Market Insights, Public sources, Desk research
We have leveraged AI tools to mine information and compile it
